Novartis (NVS) to Release Earnings on Friday

Novartis (NYSE:NVS) will likely be releasing its earnings data before the market opens on Friday, January 31st. Analysts expect Novartis to post earnings of $1.80 per share and revenue of $12.86 billion for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The company had revenue of $12.82 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter in the previous year, the company earned $1.74 EPS. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Trading Up 1.2 %

Shares of NVS stock opened at $103.09 on Thursday. The stock has a fifty day simple moving average of $100.07 and a two-hundred day simple moving average of $108.57. Novartis has a 52-week low of $92.35 and a 52-week high of $120.92. The firm has a market capitalization of $210.72 billion, a PE ratio of 11.97, a PEG ratio of 1.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11.

Analysts Set New Price Targets

Several brokerages recently issued reports on NVS. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. BMO Capital Markets boosted their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Finally, HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating and six have given a hold rating to the stock. According to MarketBeat.com, Novartis has a consensus rating of “Hold” and an average target price of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.